# Neurocrine Expects INGREZZA Revenue Growth in 2027 on Volume Gains

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/47297
Published: 2026-11-03T04:33:56.000Z
Updated: 2026-11-03T04:33:56.000Z
Section: Business

> Chief Financial Officer Matthew Abernethy expects double-digit volume growth to outweigh pricing pressure. Formal 2027 sales guidance is due in February.

Neurocrine Biosciences expects INGREZZA revenue to rise again in 2027 as double-digit volume growth more than offsets anticipated mid- to high-single-digit net pricing pressure, Chief Financial Officer Matthew Abernethy said Monday, Nov. 2.

“Looking ahead to 2027, we expect continued double-digit INGREZZA volume growth to more than offset anticipated mid- to high single-digit net pricing headwinds, supporting another year of revenue growth,” Abernethy said on the company’s earnings call.

Neurocrine has not set a numerical 2027 sales target. Abernethy said formal guidance will come in February 2027, adding, “As customary, we will provide formal 2027 sales guidance in February.”

INGREZZA net product sales totaled $801 million in the third quarter ended Sept. 30, up 17% from a year earlier. Neurocrine attributed the increase to double-digit volume growth and reported record total and new prescriptions.

Neurocrine now projects 2026 INGREZZA net sales of $2.90 billion to $2.925 billion, up from its prior estimate of $2.825 billion to $2.875 billion. Third-quarter sales included a $20 million benefit from customer order timing. Management expects that benefit to reverse in the fourth quarter, and the reversal is included in the full-year outlook.

CEO Kyle W. Gano said Neurocrine expects payer coverage and access for INGREZZA in 2027 to be at least as strong as in 2026. INGREZZA’s active ingredient is valbenazine. The medicine is used to treat tardive dyskinesia and chorea associated with Huntington’s disease.